Short Interest in FibroBiologics Inc. (NASDAQ:FBLG) Grows By 30.1%

FibroBiologics Inc. (NASDAQ:FBLG) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 873,527 shares, an increase of 30.1% from the February 26th total of 671,279 shares. Based on an average daily trading volume, of 1,498,900 shares, the short-interest ratio is currently 0.6 days. Currently, 1.5% of the company’s stock are short sold.

Insider Buying and Selling at FibroBiologics

In related news, CFO Jason Davis acquired 3,500 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $8.20 per share, for a total transaction of $28,700.00. Following the acquisition, the chief financial officer directly owned 3,500 shares of the company’s stock, valued at approximately $28,700. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders bought 9,574 shares of company stock valued at $72,886. 13.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On FibroBiologics

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd increased its stake in FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after acquiring an additional 28,276 shares during the period. AQR Capital Management LLC acquired a new stake in shares of FibroBiologics during the 1st quarter worth $29,000. Cerity Partners LLC increased its position in shares of FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after purchasing an additional 34,702 shares during the period. Geode Capital Management LLC increased its position in shares of FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after purchasing an additional 59,813 shares during the period. Finally, Marshall Wace LLP acquired a new position in FibroBiologics in the second quarter valued at about $49,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “hold” rating on shares of FibroBiologics in a research report on Thursday, March 26th. HC Wainwright reduced their price objective on FibroBiologics to $80.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $110.00.

FibroBiologics Stock Down 42.1%

Shares of FibroBiologics stock traded down $0.96 during trading on Tuesday, reaching $1.32. The company’s stock had a trading volume of 7,348,611 shares, compared to its average volume of 143,063. The business’s 50-day moving average price is $5.93 and its 200-day moving average price is $6.91. FibroBiologics has a 52 week low of $1.26 and a 52 week high of $30.60. The firm has a market cap of $92.74 million, a PE ratio of -3.14 and a beta of -0.69.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($1.80) by $1.20. Equities analysts predict that FibroBiologics will post -0.53 earnings per share for the current year.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.